<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30405600</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic-eCollection">            <Journal>                <ISSN IssnType="Electronic">1664-3224</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>9</Volume>                    <PubDate>                        <Year>2018</Year>                    </PubDate>                </JournalIssue>                <Title>Frontiers in immunology</Title>                <ISOAbbreviation>Front Immunol</ISOAbbreviation>            </Journal>            <ArticleTitle>An RORγt Oral Inhibitor Modulates IL-17 Responses in Peripheral Blood and Intestinal Mucosa of Crohn's Disease Patients.</ArticleTitle>            <Pagination>                <MedlinePgn>2307</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.3389/fimmu.2018.02307</ELocationID>            <Abstract>                <AbstractText><b>Background and Aims:</b> Despite the negative results of blocking IL-17 in Crohn's disease (CD) patients, selective modulation of Th17-dependent responses warrants further study. Inhibition of retinoic acid-related orphan receptor gamma (RORγt), the master regulator of the Th17 signature, is currently being explored in inflammatory diseases. Our aim was to determine the effect of a novel oral RORγt antagonist (BI119) in human CD and on an experimental model of intestinal inflammation. <b>Methods:</b> 51 CD patients and 11 healthy subjects were included. The effects of BI119 were tested on microbial-stimulated peripheral blood mononuclear cells (PBMCs), intestinal crypts and biopsies from CD patients. The ability of BI119 to prevent colitis <i>in vivo</i> was assessed in the CD4<sup>+</sup>CD45RB<sup>high</sup> T cell transfer model. <b>Results:</b> In bacterial antigen-stimulated PBMCs from CD patients, BI119 inhibits Th17-related genes and proteins, while upregulating Treg and preserving Th1 and Th2 signatures. Intestinal crypts cultured with supernatants from BI119-treated commensal-specific CD4<sup>+</sup> T cells showed decreased expression of <i>CXCL1, CXCL8</i> and <i>CCL20</i>. BI119 significantly reduced <i>IL17</i> and <i>IL26</i> transcription in colonic and ileal CD biopsies and did not affect <i>IL22</i>. BI119 has a more profound effect in ileal CD with additional significant downregulation of <i>IL23R, CSF2, CXCL1, CXCL8</i>, and <i>S100A8</i>, and upregulation of <i>DEFA5</i>. BI119 significantly prevented development of clinical, macroscopic and molecular markers of colitis in the T-cell transfer model. <b>Conclusions:</b> BI119 modulated CD-relevant Th17 signatures, including downregulation of <i>IL23R</i> while preserving mucosa-associated IL-22 responses, and abrogated experimental colitis. Our results provide support to the use of RORγt antagonists as a novel therapy to CD treatment.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Bassolas-Molina</LastName>                    <ForeName>Helena</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Raymond</LastName>                    <ForeName>Ernest</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Labadia</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Wahle</LastName>                    <ForeName>Joseph</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ferrer-Picón</LastName>                    <ForeName>Elena</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Panzenbeck</LastName>                    <ForeName>Mark</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Zheng</LastName>                    <ForeName>Jie</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Harcken</LastName>                    <ForeName>Christian</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hughes</LastName>                    <ForeName>Robert</ForeName>                    <Initials>R</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Turner</LastName>                    <ForeName>Michael</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>Dustin</ForeName>                    <Initials>D</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Small Molecule Discovery Research, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Calderón-Gómez</LastName>                    <ForeName>Elisabeth</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Esteller</LastName>                    <ForeName>Míriam</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Carrasco</LastName>                    <ForeName>Anna</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, Hospital Universitari Mutua Terrassa, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Esteve</LastName>                    <ForeName>Maria</ForeName>                    <Initials>M</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, Hospital Universitari Mutua Terrassa, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                    <AffiliationInfo>                        <Affiliation>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Dotti</LastName>                    <ForeName>Isabella</ForeName>                    <Initials>I</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Corraliza</LastName>                    <ForeName>Ana Maria</ForeName>                    <Initials>AM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Masamunt</LastName>                    <ForeName>Maria Carme</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Arajol</LastName>                    <ForeName>Clàudia</ForeName>                    <Initials>C</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Guardiola</LastName>                    <ForeName>Jordi</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, Hospital Universitari de Bellvitge-IDIBELL, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Ricart</LastName>                    <ForeName>Elena</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Nabozny</LastName>                    <ForeName>Gerald</ForeName>                    <Initials>G</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Immunology and Respiratory, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT, United States.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Salas</LastName>                    <ForeName>Azucena</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Gastroenterology, IDIBAPS, Hospital Clínic, CIBERehd, Barcelona, Spain.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>10</Month>                <Day>22</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Switzerland</Country>            <MedlineTA>Front Immunol</MedlineTA>            <NlmUniqueID>101560960</NlmUniqueID>            <ISSNLinking>1664-3224</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Crohn's disease</Keyword>            <Keyword MajorTopicYN="N">RORγt inhibition</Keyword>            <Keyword MajorTopicYN="N">T-cell-transfer</Keyword>            <Keyword MajorTopicYN="N">Th17</Keyword>            <Keyword MajorTopicYN="N">commensal antigens</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>07</Month>                <Day>05</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>09</Month>                <Day>17</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30405600</ArticleId>            <ArticleId IdType="doi">10.3389/fimmu.2018.02307</ArticleId>            <ArticleId IdType="pmc">PMC6204372</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>